Media News

Jacobio Pharma Announces 2022 Interim Results

Investment in R&D increased 26.3% to RMB 221 million. Recorded revenue was RMB 54.7 million. Global development of KRAS G12C inhibitor and other clinical stage drug candidates accelerated. Development started in new pre-clinical stage drug candidates, such as iADC (immunostimulatory antibody-drug conjugate), P53, and PARP7. BEIJING, SHANGHAI and BOSTON, Aug. 24, 2022...

I-Mab Announces Share Purchase Plans by the Company and the Senior Management

GAITHERSBURG, Md. and SHANGHAI, Aug. 23, 2022 /PRNewswire/ -- I-Mab ("I-Mab" or the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced that it plans to implement share repurchases pursuant to the share repurchase program previously authorized by its Board of Directors. On...

Clarity advances to cohort 3 of the CL04 trial of SARTATE™ in paediatric neuroblastoma

Highlights Cohort 2 completed in participants with neuroblastoma who received therapy with 67Cu SARTATE™ at a dose of 175MBq/kg body weight No Dose Limiting Toxicities (DLTs) have been reported in cohort 1 and cohort 2 Safety Review Committee (SRC) has recommended the trial continues with the dose escalation phase as planned...

IMG Renews Sponsorship with School the World, Employees to Go on Corporate Service Trip

INDIANAPOLIS, Aug. 23, 2022 /PRNewswire/ -- International Medical Group® (IMG®), an award-winning global insurance benefits and assistance services company, is excited to announce its sponsorship with School the World, an organization focused on providing access to quality education in Central America. As part of the sponsorship, IMG will be sending a group...

BIORCHESTRA appointed Dr. Gabriel Helmlinger (Ph.D., DABT) as Head of Translational and Clinical Pharmacology, Toxicology

BOSTON, Mass., Aug. 23, 2022 /PRNewswire/ -- BIORCHESTRA, headquartered in Daejeon, South Korea, appointed Dr. Gabriel Helmlinger (Ph.D., D.A.B.T.) as Vice-President, Head of Translational & Clinical Pharmacology, Toxicology. Dr. Helmlinger brings 25 years of drug research and clinical development experience in the biotech and global pharmaceutical industries. Prior to joining BIORCHESTRA, he...

MGI Honored with 2022 Stevie® Award for Most Valuable COVID-19 Corporate Response

SHENZHEN, China, Aug. 23, 2022 /PRNewswire/ -- MGI Tech Co. Ltd. (MGI), a global life science leader and innovator, was named the winner of a Silver Stevie® Award for Most Valuable Corporate Response in the COVID-19 category as part of the 19th Annual International Business Awards. This marked the second time in the past two months MGI was recognized...

Firmenich Receives SBTi Approval For Net-Zero Emissions Target

Firmenich is the first company in the industry to receive approval from the Science Based Targets initiative (SBTi) for its net-zero emissions target GENEVA, Aug. 23, 2022 /PRNewswire/ -- Firmenich, the world's largest privately-owned fragrance and taste company, has received approval from the Science Based Targets initiative (SBTi) for its net-zero emissions...

GenScript ProBio Congratulates Selecxine on FDA Clearance of IND Application for Innovative Antibody Drug Program

NANJING, China, Aug. 23, 2022 /PRNewswire/ -- Recently, Selecxine, a partner of GenScript ProBio, announces FDA clearance of its IND application for innovative antibody drug program (SLC-3010). GenScript ProBio was responsible for the CMC development and supporting IND filing in this project. GenScript ProBio extends congratulations on this. In December 2019, GenScript...

Announcement of 2022 Future Science Prize Winners: Wenhui Li, Xueming Yang, Ngaiming Mok

BEIJING, Aug. 23, 2022 /PRNewswire/ -- The Future Science Prize committee announces the winners of 2022 on August 21st. Prof. Wenhui Li from National Institute of Biological Sciences, Beijing, China; Tsinghua Institute of Multidisciplinary Biomedical Research receives the Future Science Prize in life sciences for his discovery of the Hepatitis B and D virus receptor, sodium taurocholate cotransporting polypeptide (NTCP)....

Brii Biosciences Appoints Eleanor de Groot as Chief Technology Officer and Aleksandar Skuban as Central Nervous System Diseases Therapy Area Head

Building a leadership team with global and local experience and expertise to enable rapid execution across Company's broad therapeutic strategy DURHAM, N.C. and BEIJING, Aug. 23, 2022 /PRNewswire/ -- Brii Biosciences Limited ("Brii Bio" or the "Company", stock code: 2137.HK), a multi-national company developing innovative therapies for diseases with significant unmet medical...